Key points from article :
Vandria SA, a pioneering biotech company specialising in mitochondrial therapeutics, has successfully raised $30.7 million in its Series A funding round, with notable contributions from Hevolution Foundation and Dolby Family Ventures. This funding boost will enable Vandria to progress its lead compound, VNA-318, into clinical development. VNA-318 is a first-in-class mitophagy inducer designed to clear damaged mitochondria from cells, which is crucial in treating neurodegenerative diseases. With its dual mode of action, VNA-318 promises immediate cognitive improvements as well as long-term disease-modifying effects, making it a promising candidate for conditions such as Alzheimer’s and Parkinson’s disease. The company plans to begin Phase 1 trials in the coming weeks, followed by additional efficacy studies in 2025.
Beyond VNA-318, Vandria is also expanding its research into other age-related and chronic diseases that affect the muscle, lung, and liver, positioning the company at the forefront of a new wave of mitochondrial-based therapies. This recent funding round, which follows an initial close at $20.6 million in December, not only enables Vandria to continue advancing its innovative platform but also strengthens its position in the competitive field of neurodegenerative and chronic disease treatment. With the addition of high-profile investors and the expansion of its team and facilities, Vandria is well-equipped to lead the development of therapies that could significantly improve health outcomes for aging populations worldwide.
